How do you think the BEATcc trial will change management of patients with advanced or recurrent cervical cancer?

Do you plan on incorporating atezolizumab into your management of patients with metastatic/recurrent cervical cancer?

• Yes, in the frontline setting
• Only in the recurrent setting
• No, I plan to use pembrolizumab only
• I will use patient and disease factors to decide which immunotherapy I will use
• Other